Mark Iwicki

Mark Iwicki

Chief Executive Officer and DirectoratInhibikase Therapeutics· In proxies 2024–2025

Pay in FY2025Inhibikase Therapeutics stock -36.9% the same year

Mark Iwicki was paid $30.6M in FY2025 (Dec). Inhibikase Therapeutics stock fell 36.9% that year.

Pay$100 in the stock at the end of FY24 → $63
Pay is from the Summary Compensation Table of each Inhibikase Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Inhibikase TherapeuticsPublic company · 2 yr
    • Chief Executive Officer and Director2024 – Present · 2 yrStock in role +32%
  2. Q32 Bio Inc.Public company · 6 yr
    • Director2020 – Present · 6 yrNo stock prices for these years
  3. Akero TherapeuticsPublic company · 7 yr
    • Director2018 – 2025 · 7 yrNo stock prices for these years
  4. Pulmatrix Inc.Public company · 6 yr
    • Director2015 – 2021 · 6 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?